Navigation Links
MiddleBrook Pharmaceuticals Reports First Quarter 2008 Results
Date:5/13/2008

ompany is developing anti-infective drugs based on its novel biological finding that bacteria exposed to antibiotics in front-loaded staccato bursts, or "pulses," are killed more efficiently and effectively than those under standard treatment regimens. Based on this finding, MiddleBrook has developed a proprietary, once-a-day pulsatile delivery technology called PULSYS(R). The Company currently markets the Keflex(R) brand of cephalexin and has received regulatory approval for MOXATAG(TM) -- the first and only once-daily amoxicillin product approved for marketing in the U.S. For more on MiddleBrook, please visit http://www.middlebrookpharma.com.

ABOUT MOXATAG:

MOXATAG(TM) (amoxicillin extended-release) Tablets are a once-a-day extended-release formulation of amoxicillin for oral administration consisting of three components: one immediate-release and two delayed-release. The three components are combined in a specific ratio to prolong the release of amoxicillin from MOXATAG compared to immediate-release amoxicillin. MOXATAG is intended to provide a lower treatment dose, once-daily alternative to currently approved penicillin and amoxicillin regimens for the treatment of adults and pediatric patients 12 years and older with tonsillitis and/or pharyngitis.

ABOUT KEFLEX:

Keflex(R) (cephalexin capsules, USP) is a first-generation cephalosporin antibiotic shown to be active against strains of both gram-positive and gram-negative aerobes in vitro and in clinical infections. Keflex is indicated for treatment of the following infections: respiratory tract infections, otitis media, skin and skin structure infections, bone infections, and genitourinary tract infections. More information on Keflex and prescribing information are available at http://www.middlebrookpharma.com/products_antibioti
'/>"/>

SOURCE MiddleBrook Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine news :

1. MiddleBrook Pharmaceuticals Raises Up to $10 Million from Deerfield Management
2. MiddleBrook Pharmaceuticals Reports Third Quarter 2007 Results
3. MiddleBrook Pharmaceuticals to Raise $21 Million Through Private Placement of Common Equity
4. MiddleBrook Pharmaceuticals Engages Morgan Stanley in Its Strategic Process
5. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
6. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
7. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
8. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
9. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
10. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
11. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... ... August 03, 2015 , ... The ... (ICC) announce an agreement to collaborate across a wide range of initiatives ... building code knowledge among architects. , “Our combined membership, consisting of practicing design ...
(Date:8/2/2015)... ... August 03, 2015 , ... A new Phase I research study is ... study is led by Kenneth G. Lucas, M.D. , chief of the division ... with colleagues at Kosair Children’s Hospital and in the UofL Department ...
(Date:8/1/2015)... (PRWEB) , ... August 02, 2015 , ... AlignLife ... which will help the continuity of care for patients at this natural health care ... the unknown," Clinic Director Mary Heal said. "Heather's role is vital to our approach ...
(Date:8/1/2015)... ... 01, 2015 , ... The condition where veins are enlarged and gnarled is ... pain and discomfort. Those who spend a lot of time on their feet and ... is doing what it can to create awareness and provide a cure in observance ...
(Date:8/1/2015)... Greenwich, CT (PRWEB) , ... August 01, 2015 ... ... Great Point Partners I, L.P. (“GPP”) portfolio company has acquired Premier Physical Therapy ... incorporating it into its portfolio of state-of-the-art clinics. , “Our acquisition of Premier ...
Breaking Medicine News(10 mins):Health News:Architects, International Code Council Ink Five-Year Collaborative Agreement 2Health News:Architects, International Code Council Ink Five-Year Collaborative Agreement 3Health News:UofL Physicians Conducting Vaccine Trial for Children with Relapsed Tumors at Kosair Children’s Hospital 2Health News:New Patient Advocate Enhances Natural Health Care 2Health News:Northeast Houston Vein Center Warns Men about Varicose Veins 2Health News:Northeast Houston Vein Center Warns Men about Varicose Veins 3Health News:Professional Physical Therapy Now Largest Outpatient Physical Therapy Provider in Northeast With Acquisition of Premier Physical Therapy & Wellness 2
... Ben-Gurion University of the Negev researcher has achieved a ... mouse cells. "This study may open new therapeutic ... pre-pubertal cancer patients at risk of infertility due to ... in adult patients," explains Prof. Mahmoud Huleihel, of BGU,s ...
... Training basic surgical techniques on toy animals before having to ... anxious. At the same time, the use of laboratory animals ... from LIFE - the Faculty of Life Sciences at the ... known as the ,teddy laboratory, strengthens learning and the teaching ...
... Amanda Gardner HealthDay Reporter , MONDAY, Nov. 14 ... of the brain seem to be involved in "chemo brain," ... treatments for breast cancer. According to research in the ... areas of the brain that are involved in planning, attention ...
... 15 (HealthDay News) -- Brainy children are at increased risk ... study says. Researchers analyzed data from nearly 8,000 people ... education and socioeconomic status. The participants, IQ scores were checked ... illegal drugs (marijuana, cocaine, uppers, downers, LSD and heroin) was ...
... Steven Reinberg HealthDay Reporter , TUESDAY, Nov. 15 ... to the statin drug Zocor (simvastatin) to help lower their ... Even though niacin appeared to increase HDL cholesterol -- ... fat in the blood, it did not reduce the risk ...
... breakthrough in understanding what stops a common form of skin ... available to the public in five years. ... Cancer Cell , an international team of scientists led ... University,s Department of Medicine at the Alfred Hospital, has discovered ...
Cached Medicine News:Health News:Surgery on toy animals lessens anxiety of veterinary students 2Health News:Breast Cancer Chemo Tied to Memory Troubles 2Health News:Breast Cancer Chemo Tied to Memory Troubles 3Health News:Smart Kids More Likely to Try Illicit Drugs as Young Adults 2Health News:No Benefit From Niacin for Heart Patients in Study 2Health News:No Benefit From Niacin for Heart Patients in Study 3Health News:Stop signal discovered for skin cancer 2
(Date:8/2/2015)... -- Mandatory takeover offer for the ... the "Company") is pleased to announce the signing of ... Marijan Han žeković to acquire his 63.3% holding (equivalent ... Croatian listed pharmaceutical business.   Dechra is ... €51.4 million for the entire share capital on a ...
(Date:7/31/2015)... CHAPEL HILL, N.C. , July 31, 2015 ... to product success in the biopharmaceutical market. Patients ... the process of selecting and switching therapies. This ... and is pushing marketers, efforts toward patient-focused marketing. ... to patient engagement, marketers have learned it,s important ...
(Date:7/31/2015)...  Seeger Weiss LLP is reporting that on July 13, ... to C.R. Bard, the manufacturer of Inferior vena cava ... violations the agency found at two of Bard,s facilities. Bard ... cited them during Inspectional Observations that occurred on November 18, ... AZ , location and on October 6, 2014, through ...
Breaking Medicine Technology:Dechra to Acquire 63.3% Shareholding (£19.4m) in Genera d.d. Croatia 2Dechra to Acquire 63.3% Shareholding (£19.4m) in Genera d.d. Croatia 3Dechra to Acquire 63.3% Shareholding (£19.4m) in Genera d.d. Croatia 4Dechra to Acquire 63.3% Shareholding (£19.4m) in Genera d.d. Croatia 5Consumers Forcing Pharmaceutical Industry to Shift its Marketing Focus from Products to Patients 2Seeger Weiss LLP Reports That The FDA Has Issued A Warning Letter To IVC Filter Manufacturer, C.R. Bard 2Seeger Weiss LLP Reports That The FDA Has Issued A Warning Letter To IVC Filter Manufacturer, C.R. Bard 3
... ... Properties - ... TRIANGLE PARK, N.C., July 22 CeNeRx BioPharma,Inc., a clinical stage company ... announced,plans to advance its lead candidate Tyrima(TM) into Phase II trials for ...
... and pegylated enzyme produces significantly enhanced survival ... ... DIEGO, July 22 Halozyme Therapeutics,Inc. (Nasdaq: HALO ), ... today,announced the presentation of positive pre-clinical animal efficacy data,for its ...
Cached Medicine Technology:CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study 2CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study 3CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study 4Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models 2Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models 3Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models 4Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models 5
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: